Latest Wilson disease Stories
STOCKHOLM, April 16, 2015 /PRNewswire/ -- Wilson Therapeutics AB, a development stage biopharmaceutical company,
The copper sequestering drug tetrathiomolybdate (TM) has been shown in studies to be effective in the treatment of Wilson disease, a disease caused by an overload of copper, and certain metastatic cancers. That much is known. Very little, however, is known about how the drug works at the molecular level.
- An armed gangster.